GE HealthCare Launches Flyrcado Injection to Treat CAD

March 27, 2025—GE HealthCare announced the United States launch of Flyrcado (flurpiridaz F 18) injection, which received FDA approval in 2024 for patients with known or suspected coronary artery disease. Flyrcado is intended to deliver higher diagnostic efficacy compared to single-photon emission computed tomography myocardial perfusion imaging (MPI), stated the company.

The Flyrcado unit-dose positron emission tomography (PET) MPI agent is now available in select United States markets, advised GE HealthCare.

The company noted that the launch coincides with the receipt of pass-through status by the Centers for Medicare & Medicaid Services.

Effective April 1, the pass-through status secures a drug-specific Healthcare Common Procedure Coding System (HCPCS) billing code and coverage for traditional Medicare beneficiaries. Pass-through payment status will enable CMS to provide separate payments for the radiopharmaceutical and the PET-CT scan, when performed with Flyrcado in the hospital outpatient setting, advised GE HealthCare.

The company will introduce Flyrcado on March 29 at ACC.25, the American College of Cardiology’s annual scientific session held March 29-31 in Chicago, Illinois.